Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Trifluridine/Tipiracil Effective in Metastatic Gastric Cancer After Gastrectomy

Publish date:: November 4, 2019

Key clinical point: Trifluridine/tipiracil had acceptable toxicities and efficacy in patients with mGC/GEJC with or without gastrectomy.

Major finding: In patients who had gastrectomies, the hazard ratio for OS of patients treated with FTD/TPI vs. placebo was 0.57 and the HR for PFS was 0.48.

Study details: Preplanned subgroup analysis of 507 patients with metastatic gastric or gastroesophageal junction cancer.

Disclosures: The study was funded by Taiho Oncology and Taiho Pharmaceutical Company. Dr. Islon reported grants and advisory role support from Taiho and others. Multiple coauthors had similar disclosures.

Citation:

Ilson DH et al. JAMA Oncol. 2019 Oct 10. doi: 10.1001/jamaoncol.2019.3531.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Gastroenterology

Younger adults present with more advanced esophageal adenocarcinoma,

DOACs look safe in elective endoscopic procedures,

Upper GI bleeds in COVID-19 not related to increased mortality,

Cryoballoon, cryospray found equivalent for eradicating Barret’s esophagus,